JOHNSON & JOHNSON

NYSE: JNJ (Johnson & Johnson)

Last update: 12 hours ago

164.47

0.19 (0.12%)

  • 1D 0.12%
  • 5D 2.47%
  • 1M -1.01%
  • 6M 12.85%
  • YTD 2.81%
  • 1Y 7.69%
  • 5Y 28.79%
Previous Close 164.28
Open 164.26
Volume 4,549,887
Avg. Volume (3M) 6,477,060
Market Cap 395,918,770,176
Price / Earnings (TTM) 27.19
Price / Earnings (Forward) 15.11
Price / Sales 4.55
Price / Book 5.53
52 Weeks Range
143.13 (-12%) — 168.85 (2%)
Earnings Date 15 Oct 2024
TTM Dividend Yield 2.96%
Profit Margin 16.74%
Operating Margin (TTM) 23.67%
Diluted EPS (TTM) 6.05
Quarterly Revenue Growth (YOY) 5.20%
Quarterly Earnings Growth (YOY) -89.70%
Total Debt/Equity (MRQ) 58.00%
Current Ratio (MRQ) 1.07
Return on Assets (TTM) 8.10%
Return on Equity (TTM) 22.15%

Market Trend

Short Term Medium Term
Industry Drug Manufacturers - General (US) Bullish Bullish
Drug Manufacturers - General (Global) Bullish Bullish
Stock Johnson & Johnson Bullish Bullish

Stockmoo Score

0.8
Analyst Consensus 1.5
Insider Activity NA
Price Volatility -0.5
Technical Moving Averages 0.0
Technical Oscillators 2.0
Average 0.75

Similar Stocks

Stock Market Cap DY P/E P/B
JNJ 396 B 2.96% 27.19 5.53
ABBV 285 B 2.84% 48.13 49.63
MRK 278 B 2.81% 20.32 6.36
PFE 166 B 5.71% - 1.92
BMY 106 B 4.52% - 6.36
GSK 79 B 2.94% 13.89 4.26

Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: pharmaceutical and medical devices. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. Geographically, just over half of total revenue is generated in the United States.
Sector Healthcare
Industry Drug Manufacturers - General
Investment Style Large Value
% Held by Insiders 0.09%
% Held by Institutions 72.57%
52 Weeks Range
143.13 (-12%) — 168.85 (2%)
Price Target Range
150.00 (-8%) — 215.00 (30%)
High 215.00 (Cantor Fitzgerald, 30.72%) Buy
Median 178.00 (8.23%)
Low 150.00 (Daiwa Capital, -8.80%) Hold
Average 176.50 (7.31%)
Total 4 Buy, 4 Hold
Avg. Price @ Call 160.48
Firm Date Target Price Call Price @ Call
Cantor Fitzgerald 16 Oct 2024 215.00 (30.72%) Buy 164.28
10 Oct 2024 215.00 (30.72%) Buy 160.51
Citigroup 16 Oct 2024 185.00 (12.48%) Buy 164.28
Morgan Stanley 16 Oct 2024 175.00 (6.40%) Hold 164.28
18 Jul 2024 169.00 (2.75%) Hold 155.42
RBC Capital 16 Oct 2024 181.00 (10.05%) Buy 164.28
08 Oct 2024 178.00 (8.23%) Buy 159.69
Wells Fargo 16 Oct 2024 166.00 (0.93%) Hold 164.28
Daiwa Capital 23 Jul 2024 150.00 (-8.80%) Hold 152.35
Goldman Sachs 19 Jul 2024 155.00 (-5.76%) Hold 154.69
TD Cowen 18 Jul 2024 185.00 (12.48%) Buy 155.42
Show more

No data within this time range.

  • 3M
Date Type Details
15 Oct 2024 Announcement Nipocalimab demonstrates sustained disease control in adolescents living with generalized myasthenia gravis in Phase 2/3 study
15 Oct 2024 Announcement Johnson & Johnson Reports Q3 2024 Results
15 Oct 2024 Announcement Connecticut Jury Delivers $15 Million Asbestos Verdict Against Johnson & Johnson
15 Oct 2024 Announcement Johnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2024
10 Oct 2024 Announcement TREMFYA® (guselkumab) demonstrates impressive results across biologic-naïve and biologic-refractory patients in Crohn's disease and ulcerative colitis
10 Oct 2024 Announcement Johnson & Johnson to Participate in the Stifel 2024 Healthcare Conference
09 Oct 2024 Announcement Johnson & Johnson Completes Acquisition of V-Wave
04 Oct 2024 Announcement Johnson & Johnson to Participate in the Guggenheim Global Healthcare Conference
02 Oct 2024 Announcement ERLEADA® (apalutamide) demonstrates statistically significant and clinically meaningful improvement in overall survival compared to enzalutamide in patients with metastatic castration-sensitive prostate cancer
30 Sep 2024 Announcement Johnson & Johnson Rolls Out New TECNIS Odyssey Next-Generation Intraocular Lens Offering Cataract Patients Precise Vision at Every Distance in Any Lighting
30 Sep 2024 Announcement Johnson & Johnson files for U.S. FDA approval of DARZALEX FASPRO®-based quadruplet regimen for newly diagnosed multiple myeloma patients for whom transplant is not planned
27 Sep 2024 Announcement DARZALEX FASPRO®-based quadruplet regimen significantly improves minimal residual disease negativity for newly diagnosed multiple myeloma patients for whom transplant is not planned
27 Sep 2024 Announcement CARVYKTI® is the first and only cell therapy to significantly extend overall survival versus standard therapies for patients with multiple myeloma as early as second line
27 Sep 2024 Announcement Novel combination of TALVEY® (talquetamab-tgvs) and TECVAYLI® (teclistamab-cqyv) suggests high response rates and durable responses in triple-class refractory patients with relapsed or refractory multiple myeloma, including those with extramedullary d...
27 Sep 2024 Announcement DARZALEX® (daratumumab)-based maintenance regimens show clinically meaningful deep and durable responses in transplant-eligible patients with newly diagnosed multiple myeloma
27 Sep 2024 Announcement TALVEY® (talquetamab-tgvs) and DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) based combination shows deep and durable responses in patients with relapsed or refractory multiple myeloma
20 Sep 2024 Announcement Johnson & Johnson Announces that its Subsidiary, Red River Talc LLC, has Filed a Voluntary Prepackaged Chapter 11 Case to Resolve All Current and Future Ovarian Cancer Talc Claims
20 Sep 2024 Announcement Attorneys Vow to Oppose J&J’s Third Bankruptcy Attempt
19 Sep 2024 Announcement RYBREVANT® (amivantamab-vmjw) plus standard of care approved in the U.S. as first and only targeted regimen to cut risk of disease progression by more than half in second-line EGFR-mutated advanced lung cancer
16 Sep 2024 Announcement Neoadjuvant TAR-200 plus cetrelimab nearly doubles the pathological complete response rate compared to cetrelimab alone in patients with muscle-invasive bladder cancer
15 Sep 2024 Announcement New data from TAR-200 Phase 2b SunRISe-1 study show 84 percent complete response rate in patients with high-risk non-muscle-invasive bladder cancer
14 Sep 2024 Announcement RYBREVANT® (amivantamab-vmjw) plus chemotherapy shows positive overall survival trend versus chemotherapy in patients with previously treated EGFR-mutated lung cancer
14 Sep 2024 Announcement RYBREVANT® (amivantamab-vmjw) plus chemotherapy show 49 percent overall response rate in metastatic colorectal cancer
11 Sep 2024 Announcement TREMFYA® (guselkumab) receives U.S. FDA approval for adults with moderately to severely active ulcerative colitis, strengthening Johnson & Johnson's leadership in inflammatory bowel disease
10 Sep 2024 Announcement Dexamethasone reduces infusion-related reactions in patients with EGFR-mutated non-small cell lung cancer treated with intravenous RYBREVANT® (amivantamab-vmjw)
08 Sep 2024 Announcement RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) show strong favorable overall survival trend versus osimertinib in EGFR-mutated advanced lung cancer
05 Sep 2024 Announcement Johnson & Johnson to Host Investor Conference Call on Third-Quarter Results
29 Aug 2024 Announcement Johnson & Johnson seeks first approval of nipocalimab to treat broadest population living with antibody positive generalized myasthenia gravis
27 Aug 2024 Announcement Johnson & Johnson is transforming solid tumor cancer outcomes with new data at the 2024 World Conference on Lung Cancer and European Society for Medical Oncology Congress
26 Aug 2024 Announcement Johnson & Johnson’s Executive Vice President, Chief Human Resources Officer Peter Fasolo to Retire; Kristen Mulholland Named Chief Human Resources Officer, Effective October 1, 2024
20 Aug 2024 Announcement Johnson & Johnson to Acquire V-Wave
20 Aug 2024 Announcement RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) approved in the U.S. as a first-line chemotherapy-free treatment for patients with EGFR-mutated advanced lung cancer
15 Aug 2024 CNBC Biden administration releases prices of 10 drugs in Medicare negotiations, says U.S. will save $6 billion in first year
15 Aug 2024 Announcement South Carolina Jury Awards $63.4 Million to Johnson & Johnson Asbestos Victim
13 Aug 2024 Announcement Lawyers for Ovarian Cancer Victims Endorse Proposed Texas Two-Step Remedy
07 Aug 2024 Announcement Groundbreaking nipocalimab study of pregnant individuals at high risk for early onset severe hemolytic disease of the fetus and newborn published in The New England Journal of Medicine
06 Aug 2024 CNBC Healthy Returns: What drugmakers are saying about final negotiated prices with Medicare
02 Aug 2024 Announcement DePuy Synthes Launches its First Active Spine Robotics and Navigation Platform
30 Jul 2024 Announcement DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based quadruplet regimen approved in the U.S. for patients with newly diagnosed multiple myeloma who are transplant-eligible
29 Jul 2024 Announcement Johnson & Johnson to Participate in the 2024 Wells Fargo Healthcare Conference
26 Jul 2024 Announcement Courts, Congress Likely to Stand in Way of J&J’s Third Texas Two-Step Plan
26 Jul 2024 Announcement FINAL DEADLINE: Ovarian Cancer Victims Have Until 5pm ET Today to Vote on Approximately $8 Billion J&J Talc Compensation Plan
25 Jul 2024 TheFinance 5 US Growth Stalwarts That Dish Out Increasing Dividends
23 Jul 2024 Announcement Johnson & Johnson to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
22 Jul 2024 Announcement Lawyers for Ovarian Cancer Victims Urge NO Vote on J&J’s Latest Bankruptcy Plan
22 Jul 2024 Announcement Johnson & Johnson seeks U.S. FDA approval of SPRAVATO® (esketamine) as the first and only monotherapy for adults with treatment-resistant depression
Show more
TTM Dividend Yield 2.96%
5Y Average Dividend Yield 2.61%
Payout Ratio 80.33%
Expected Next Dividend Payment Dec 2024
Ex Date Announcement Date Payment Date Details
27 Aug 2024 17 Jul 2024 10 Sep 2024 1.24 Cash
20 May 2024 16 Apr 2024 04 Jun 2024 1.24 Cash
16 Feb 2024 02 Jan 2024 05 Mar 2024 1.19 Cash
20 Nov 2023 19 Oct 2023 05 Dec 2023 1.19 Cash
25 Aug 2023 20 Jul 2023 07 Sep 2023 1.19 Cash
22 May 2023 18 Apr 2023 06 Jun 2023 1.19 Cash
17 Feb 2023 03 Jan 2023 07 Mar 2023 1.13 Cash
21 Nov 2022 19 Oct 2022 06 Dec 2022 1.13 Cash
22 Aug 2022 18 Jul 2022 06 Sep 2022 1.13 Cash
23 May 2022 19 Apr 2022 07 Jun 2022 1.13 Cash
18 Feb 2022 04 Jan 2022 08 Mar 2022 1.06 Cash
22 Nov 2021 21 Oct 2021 07 Dec 2021 1.06 Cash
23 Aug 2021 19 Jul 2021 07 Sep 2021 1.06 Cash
24 May 2021 06 May 2021 08 Jun 2021 1.06 Cash
22 Feb 2021 04 Jan 2021 09 Mar 2021 1.01 Cash
23 Nov 2020 22 Oct 2020 08 Dec 2020 1.01 Cash
24 Aug 2020 20 Jul 2020 08 Sep 2020 1.01 Cash
22 May 2020 14 Apr 2020 09 Jun 2020 1.01 Cash
24 Feb 2020 02 Jan 2020 10 Mar 2020 0.95 Cash
25 Nov 2019 18 Oct 2019 10 Dec 2019 0.95 Cash
26 Aug 2019 16 Jul 2019 10 Sep 2019 0.95 Cash
24 May 2019 26 Apr 2019 11 Jun 2019 0.95 Cash
25 Feb 2019 02 Jan 2019 12 Mar 2019 0.9 Cash
26 Nov 2018 18 Oct 2018 11 Dec 2018 0.9 Cash
27 Aug 2018 17 Jul 2018 11 Sep 2018 0.9 Cash
25 May 2018 26 Apr 2018 12 Jun 2018 0.9 Cash
26 Feb 2018 02 Jan 2018 13 Mar 2018 0.84 Cash
27 Nov 2017 19 Oct 2017 12 Dec 2017 0.84 Cash
25 Aug 2017 17 Jul 2017 12 Sep 2017 0.84 Cash
25 May 2017 27 Apr 2017 13 Jun 2017 0.84 Cash
24 Feb 2017 03 Jan 2017 14 Mar 2017 0.8 Cash
18 Nov 2016 20 Oct 2016 06 Dec 2016 0.8 Cash
19 Aug 2016 18 Jul 2016 06 Sep 2016 0.8 Cash
20 May 2016 28 Apr 2016 07 Jun 2016 0.8 Cash
19 Feb 2016 04 Jan 2016 08 Mar 2016 0.75 Cash
20 Nov 2015 22 Oct 2015 08 Dec 2015 0.75 Cash
21 Aug 2015 20 Jul 2015 08 Sep 2015 0.75 Cash
21 May 2015 23 Apr 2015 09 Jun 2015 0.75 Cash
20 Feb 2015 05 Jan 2015 10 Mar 2015 0.7 Cash
21 Nov 2014 16 Oct 2014 09 Dec 2014 0.7 Cash
22 Aug 2014 21 Jul 2014 09 Sep 2014 0.7 Cash
22 May 2014 24 Apr 2014 10 Jun 2014 0.7 Cash
21 Feb 2014 02 Jan 2014 11 Mar 2014 0.66 Cash
22 Nov 2013 17 Oct 2013 10 Dec 2013 0.66 Cash
23 Aug 2013 15 Jul 2013 10 Sep 2013 0.66 Cash
23 May 2013 25 Apr 2013 11 Jun 2013 0.66 Cash
22 Feb 2013 02 Jan 2013 12 Mar 2013 0.61 Cash
23 Nov 2012 17 Oct 2012 11 Dec 2012 0.61 Cash
24 Aug 2012 16 Jul 2012 11 Sep 2012 0.61 Cash
24 May 2012 26 Apr 2012 12 Jun 2012 0.61 Cash
24 Feb 2012 03 Jan 2012 13 Mar 2012 0.57 Cash
25 Nov 2011 21 Oct 2011 13 Dec 2011 0.57 Cash
26 Aug 2011 18 Jul 2011 13 Sep 2011 0.57 Cash
26 May 2011 28 Apr 2011 14 Jun 2011 0.57 Cash
25 Feb 2011 03 Jan 2011 15 Mar 2011 0.54 Cash
26 Nov 2010 21 Oct 2010 14 Dec 2010 0.54 Cash
27 Aug 2010 19 Jul 2010 14 Sep 2010 0.54 Cash
27 May 2010 22 Apr 2010 15 Jun 2010 0.54 Cash
19 Feb 2010 04 Jan 2010 09 Mar 2010 0.49 Cash
20 Nov 2009 22 Oct 2009 08 Dec 2009 0.49 Cash
21 Aug 2009 20 Jul 2009 08 Sep 2009 0.49 Cash
21 May 2009 23 Apr 2009 09 Jun 2009 0.49 Cash
20 Feb 2009 05 Jan 2009 10 Mar 2009 0.46 Cash
21 Nov 2008 16 Oct 2008 09 Dec 2008 0.46 Cash
22 Aug 2008 21 Jul 2008 09 Sep 2008 0.46 Cash
22 May 2008 24 Apr 2008 10 Jun 2008 0.46 Cash
22 Feb 2008 02 Jan 2008 11 Mar 2008 0.415 Cash
23 Nov 2007 18 Oct 2007 11 Dec 2007 0.415 Cash
24 Aug 2007 16 Jul 2007 11 Sep 2007 0.415 Cash
24 May 2007 26 Apr 2007 12 Jun 2007 0.415 Cash
23 Feb 2007 03 Jan 2007 13 Mar 2007 0.375 Cash
24 Nov 2006 19 Oct 2006 12 Dec 2006 0.375 Cash
25 Aug 2006 18 Jul 2006 12 Sep 2006 0.375 Cash
25 May 2006 27 Apr 2006 13 Jun 2006 0.375 Cash
18 Nov 2005 20 Oct 2005 13 Dec 2005 0.33 Cash
19 Aug 2005 18 Jul 2005 13 Sep 2005 0.33 Cash
13 May 2005 28 Apr 2005 07 Jun 2005 0.33 Cash
11 Feb 2005 04 Jan 2005 08 Mar 2005 0.285 Cash
12 Nov 2004 22 Oct 2004 07 Dec 2004 0.285 Cash
13 Aug 2004 20 Jul 2004 07 Sep 2004 0.285 Cash
14 May 2004 22 Apr 2004 08 Jun 2004 0.285 Cash
12 Feb 2004 05 Jan 2004 09 Mar 2004 0.24 Cash
14 Nov 2003 16 Oct 2003 09 Dec 2003 0.24 Cash
15 Aug 2003 22 Jul 2003 09 Sep 2003 0.24 Cash
16 May 2003 24 Apr 2003 10 Jun 2003 0.24 Cash
13 Feb 2003 06 Jan 2003 11 Mar 2003 0.205 Cash
15 Nov 2002 15 Oct 2002 10 Dec 2002 0.205 Cash
16 Aug 2002 15 Jul 2002 10 Sep 2002 0.205 Cash
17 May 2002 25 Apr 2002 11 Jun 2002 0.205 Cash
14 Feb 2002 02 Jan 2002 12 Mar 2002 0.18 Cash
16 Nov 2001 18 Oct 2001 11 Dec 2001 0.18 Cash
17 Aug 2001 16 Jul 2001 11 Sep 2001 0.18 Cash
18 May 2001 26 Apr 2001 12 Jun 2001 0.36 Cash
15 Feb 2001 02 Jan 2001 13 Mar 2001 0.32 Cash
17 Nov 2000 16 Oct 2000 12 Dec 2000 0.32 Cash
18 Aug 2000 17 Jul 2000 12 Sep 2000 0.32 Cash
19 May 2000 19 Apr 2000 13 Jun 2000 0.32 Cash
11 Feb 2000 03 Jan 2000 07 Mar 2000 0.28 Cash
12 Nov 1999 18 Oct 1999 07 Dec 1999 0.28 Cash
13 Aug 1999 19 Jul 1999 07 Sep 1999 0.28 Cash
14 May 1999 22 Apr 1999 08 Jun 1999 0.28 Cash
11 Feb 1999 04 Jan 1999 09 Mar 1999 0.25 Cash
13 Nov 1998 19 Oct 1998 08 Dec 1998 0.25 Cash
14 Aug 1998 20 Jul 1998 08 Sep 1998 0.25 Cash
15 May 1998 23 Apr 1998 09 Jun 1998 0.25 Cash
12 Feb 1998 02 Jan 1998 10 Mar 1998 0.22 Cash
14 Nov 1997 20 Oct 1997 09 Dec 1997 0.22 Cash
15 Aug 1997 21 Jul 1997 09 Sep 1997 0.22 Cash
16 May 1997 24 Apr 1997 10 Jun 1997 0.22 Cash
13 Feb 1997 02 Jan 1997 11 Mar 1997 0.19 Cash
15 Nov 1996 21 Oct 1996 10 Dec 1996 0.19 Cash
16 Aug 1996 15 Jul 1996 10 Sep 1996 0.19 Cash
17 May 1996 25 Apr 1996 11 Jun 1996 0.38 Cash
15 Feb 1996 02 Jan 1996 12 Mar 1996 0.33 Cash
10 Nov 1995 16 Oct 1995 05 Dec 1995 0.33 Cash
11 Aug 1995 17 Jul 1995 05 Sep 1995 0.33 Cash
10 May 1995 27 Apr 1995 06 Jun 1995 0.33 Cash
Show more

Annual Dividend Yield

Year Annual Dividend ($) Frequency/Year Yield %
2024 3.67 3 2.23
2023 4.70 4 3.00
2022 4.45 4 2.52
2021 4.19 4 2.45
2020 3.98 4 2.53
2019 3.75 4 2.57
2018 3.54 4 2.74
2017 3.32 4 2.38
2016 3.15 4 2.73
2015 2.95 4 2.87
2014 2.76 4 2.64
2013 2.59 4 2.83
2012 2.40 4 3.42
2011 2.25 4 3.43
2010 2.11 4 3.41
2009 1.93 4 3.00
2008 1.80 4 3.00
2007 1.62 4 2.43
2006 1.13 3 1.70
2005 1.28 4 2.12
2004 1.10 4 1.73
2003 0.925 4 1.79
2002 0.795 4 1.48
2001 1.04 4 1.76
2000 1.24 4 2.36
1999 1.09 4 2.34
1998 0.970 4 2.31
1997 0.850 4 2.58
1996 1.09 4 4.38
1995 0.990 3 4.63
Show more

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2024 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria